CO2022001257A2 - 1,2,4]triazolo[1,5-c]quinazolin-5-aminas - Google Patents

1,2,4]triazolo[1,5-c]quinazolin-5-aminas

Info

Publication number
CO2022001257A2
CO2022001257A2 CONC2022/0001257A CO2022001257A CO2022001257A2 CO 2022001257 A2 CO2022001257 A2 CO 2022001257A2 CO 2022001257 A CO2022001257 A CO 2022001257A CO 2022001257 A2 CO2022001257 A2 CO 2022001257A2
Authority
CO
Colombia
Prior art keywords
compounds
preparation
quinazolin
triazolo
amines
Prior art date
Application number
CONC2022/0001257A
Other languages
English (en)
Inventor
Benjamin Bader
Ludwig Zorn
Ulrich Bothe
Judith Günther
Michael Platten
Lars Röse
Christina Kober
Julien Lefranc
Norbert Schmees
Robin Michael Meier
Simon Anthony Herbert
Ilona Gutcher
Detlef Stöckigt
Mátyás Gorjánácz
Bernd Buchmann
Stephan Böhme
Daniel Baumann
Original Assignee
Bayer Pharma AG
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG, Bayer Ag filed Critical Bayer Pharma AG
Publication of CO2022001257A2 publication Critical patent/CO2022001257A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención comprende compuestos de [1,2,4]triazolo[1,5-c]quinazolin-5-amina de la fórmula general (I): (I) 5 en donde R1, R2, R3, R4, R5, R6, R7 y R8 son como se definen en la presente, métodos para la preparación de dichos compuestos, compuestos intermedios útiles para la preparación de dichos compuestos, composiciones farmacéuticas y combinaciones que comprenden dichos compuestos y el uso de dichos compuestos para la elaboración de composiciones farmacéuticas para el 10 tratamiento o la profilaxis de enfermedades, en especial de cáncer o afecciones con respuestas inmunes desreguladas u otros trastornos asociados con la señalización anormal de AHR, como un único agente o en combinación con otros ingredientes activos.
CONC2022/0001257A 2019-08-12 2022-02-08 1,2,4]triazolo[1,5-c]quinazolin-5-aminas CO2022001257A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19191299 2019-08-12
EP20167707 2020-04-02
PCT/EP2020/072377 WO2021028382A1 (en) 2019-08-12 2020-08-10 [1,2,4]triazolo[1,5-c]quinazolin-5-amines

Publications (1)

Publication Number Publication Date
CO2022001257A2 true CO2022001257A2 (es) 2022-03-08

Family

ID=72243077

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2022/0001257A CO2022001257A2 (es) 2019-08-12 2022-02-08 1,2,4]triazolo[1,5-c]quinazolin-5-aminas

Country Status (19)

Country Link
US (1) US20230113037A1 (es)
EP (1) EP4013508A1 (es)
JP (1) JP2022544952A (es)
KR (1) KR20220045978A (es)
CN (1) CN114466850B (es)
AU (1) AU2020328154A1 (es)
BR (1) BR112022001628A2 (es)
CA (1) CA3150544A1 (es)
CO (1) CO2022001257A2 (es)
CR (1) CR20220064A (es)
DO (1) DOP2022000031A (es)
EC (1) ECSP22009803A (es)
GE (1) GEP20247611B (es)
IL (1) IL290445A (es)
JO (1) JOP20220034A1 (es)
MX (1) MX2022001803A (es)
PE (1) PE20220967A1 (es)
TW (1) TW202126655A (es)
WO (1) WO2021028382A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4139287A1 (en) 2020-04-24 2023-03-01 Bayer Aktiengesellschaft Substituted aminothiazoles as dgkzeta inhibitors for immune activation
WO2022049253A1 (en) * 2020-09-07 2022-03-10 Bayer Aktiengesellschaft Substituted n-heteroaryl-n-pyridinylacetamides as p2x4 modulators
CN114181212B (zh) * 2020-09-15 2023-06-06 山东轩竹医药科技有限公司 哒嗪酮类AhR抑制剂
CN114621236B (zh) * 2022-04-25 2024-06-18 河南湾流生物科技有限公司 一种喹啉类饲料添加剂的制备方法
WO2024208198A1 (zh) * 2023-04-06 2024-10-10 微境生物医药科技(上海)有限公司 作为DGKζ抑制剂的噻唑类化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358964B1 (en) * 2000-07-26 2002-03-19 King Pharmaceuticals Research And Development, Inc. Adenosine, A3 receptor modulators
WO2007040565A2 (en) 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
CN103179968B (zh) 2010-07-27 2017-10-03 波士顿大学管理委员会 作为癌症疗法的芳烃受体(AhR)调节剂
WO2020102506A1 (en) * 2018-11-14 2020-05-22 The Broad Institute, Inc. Aryl hydrocarbon receptor (ahr) activator compounds as cancer therapeutics

Also Published As

Publication number Publication date
IL290445A (en) 2022-04-01
BR112022001628A2 (pt) 2022-06-21
TW202126655A (zh) 2021-07-16
DOP2022000031A (es) 2022-03-15
EP4013508A1 (en) 2022-06-22
WO2021028382A1 (en) 2021-02-18
CA3150544A1 (en) 2021-02-18
CR20220064A (es) 2022-05-04
PE20220967A1 (es) 2022-06-10
AU2020328154A1 (en) 2022-03-03
ECSP22009803A (es) 2022-03-31
US20230113037A1 (en) 2023-04-13
KR20220045978A (ko) 2022-04-13
CN114466850A (zh) 2022-05-10
MX2022001803A (es) 2022-03-11
JOP20220034A1 (ar) 2023-01-30
CN114466850B (zh) 2024-09-10
GEP20247611B (en) 2024-03-11
JP2022544952A (ja) 2022-10-24

Similar Documents

Publication Publication Date Title
DOP2019000206A (es) 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas
CO2022001257A2 (es) 1,2,4]triazolo[1,5-c]quinazolin-5-aminas
NI201900041A (es) 1, 2, 4-triazolonas 2, 4, 5-trisustituidas
DOP2018000226A (es) Nuevos derivados de pirazolopirimidina
DOP2019000117A (es) Nuevos derivados de quinolina
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CR20180556A (es) 3-oxo-2, 6-difenil-2,3-dihidropiridazin-4-carboxamidas
DOP2020000023A (es) Nuevos derivados de quinolina
CO2020001242A2 (es) Dihidrooxadiazinonas
CO2019014484A2 (es) Nuevos derivados de azaquinolina
CO2022014876A2 (es) Aminotiazoles sustituidos como inhibidores de dgkzeta para la activación inmune
ECSP034916A (es) Oxazolidinonas substituidas para terapia de combinacion
UY37149A (es) 2–amino–n–[7–metoxi–2,3–dihidroimidazo–[1,2–c]quinazolin–5–il]pirimidin–5–carboxamidas
UY37971A (es) Derivados de indol macrocíclicos sustituidos
CL2020002891A1 (es) Nuevos derivados de quinolina
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
ECSP23077322A (es) Derivados de fósforo como nuevos inhibidores de sos1
UY37972A (es) Derivados de indol macrocíclicos sustituidos con cloro
UY38816A (es) Nuevos derivados de isoquinolina